Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
07. Oktober 2020 16:05 ET
|
Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System
12. April 2018 09:29 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ CFTR NGS Library Prep Assay, a highly efficient...
Proteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Science Conference
28. März 2016 07:30 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...